SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SABS) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001833214 · SABS · NASDAQ · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001833214 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
SAB Biotherapeutics, Inc. (NASDAQ: SABS) has submitted 411 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001833214, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is SAB Biotherapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent SAB Biotherapeutics, Inc. 10-K was filed on 2026-03-09 for fiscal year ending 2026. Historical SABS 10-K annual reports are available from 2020 through 2026.
Investors researching SAB Biotherapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
SABS SEC Filings · 8 questionsSAB Biotherapeutics, Inc. (SABS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 411 filings and access original documents at no cost. SAB Biotherapeutics, Inc.'s CIK is 0001833214.